Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2003-11-01
To compare the efficacy and safety of tigecycline with those of levofloxacin in the treatment
of subjects with CAP requiring hospitalization. The co-primary efficacy endpoints in the
study will be the clinical response in the clinically evaluable population and the clinical
response in the clinical modified intent-to-treat population at the TOC visit. The primary
efficacy analyses will first determine whether tigecycline is noninferior to levofloxacin. If
tigecycline is found to be noninferior, the analyses will determine whether tigecycline is
statistically better than levofloxacin.
Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2003-10-01
To evaluate the safety and efficacy of tigecycline in the treatment of selected serious
infections caused by VRE. The primary efficacy endpoint will be the clinical response for all
subjects.
Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2003-12-01
To evaluate the safety and efficacy of tigecycline in the treatment of subjects with selected
serious infections caused by resistant gram-negative bacteria, eg, Acinetobacter baumannii,
Enterobacter species, Klebsiella pneumoniae or other resistant gram-negative pathogens, for
whom antibiotics have failed or who cannot tolerate other appropriate antimicrobial
therapies. The primary efficacy endpoint will be the clinical response.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
